P. Robinson

发表

Does Distance Decay Modelling of Supermarket Accessibility Predict Fruit and Vegetable Intake by Individuals in a Large Metropolitan Area?

Darryl B. Hood, Senait Teklehaimanot, S. Teklehaimanot, 2013, Journal of health care for the poor and underserved.

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

Paul Robinson, R. Gani, M. Cowie, 2012, Heart.

The burden of illness in patients with hyponatraemia in Sweden: a population‐based registry study

P. Sobocki, P. Robinson, M. Gisby, 2016, International journal of clinical practice.

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

M. Aristides, K. Boye, J. Bae, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model

F. Scolari, R. Sandford, G. Walz, 2018, BMC Nephrology.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

J. Plumb, G. Dolan, I. Brenkel, 2009, Clinical therapeutics.

Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden

D. Trueman, P. Robinson, M. Gisby, 2016, BMC Endocrine Disorders.

The Cost-Effectiveness of Tolvaptan for the Treatment of Hyponatraemia Secondary To Syndrome Of Inappropriate Antidiuretic Hormone Secretion in Sweden.

D. Trueman, P. Robinson, J. Lundberg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement

J. Plumb, G. Dolan, I. Brenkel, 2009, Thrombosis and Haemostasis.

PCV140 PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: A UK PILOT STUDY OF WARFARIN-NAÏVE ATRIAL FIBRILLATION PATIENTS

C. Lereun, P. Robinson, S. Cottrell, 2009 .

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.

J. Plumb, A. Tukiendorf, P. McEwan, 2009, Thrombosis research.

Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer

M. Aristides, P. Robinson, H. Maase, 2004, Expert review of pharmacoeconomics & outcomes research.

Development of a stated-preference instrument to prioritize treatment goals in recent onset schizophrenia

S. Heres, J. Bridges, K. Beusterien, 2017, Current medical research and opinion.

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease

Paul Robinson, P. Robinson, Claire Woon, 2015, BMC Nephrology.

An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom.

L. Mantovani, J. Bernier, P. Schöffski, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

PMH5 A MODELLED ECONOMIC EVALUATION OF ATOMOXETINE (STRATTERA) FOR THE TREATMENT OF THREE PATIENT GROUPS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

P. Robinson, S. Cottrell, K. Nyhus, 2005 .

PMH10 A MODELLED ECONOMIC EVALUATION COMPARING ATOMOXETINEWITH CURRENT THERAPIES FOR THE TREATMENT OF CHILDREN WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN THE NETHERLANDS

M. Aristides, P. Robinson, S. Cottrell, 2005 .

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

M. Aristides, K. Boye, J. Bae, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

EQ-5D Scores In Patients Receiving Tolvaptan for the Treatment Of Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.

D. Trueman, P. Robinson, E. Hancock, 2014, Value in Health.

The Cost-Effectiveness of Tolvaptan for the Treatment of Hyponatraemia Secondary To Syndrome Of Inappropriate Antidiuretic Hormone Secretion in Sweden.

D. Trueman, P. Robinson, J. Lundberg, 2014, Value in Health.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

J. Plumb, G. Dolan, I. Brenkel, 2009, Clinical therapeutics.